ATE384781T1 - Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes - Google Patents

Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes

Info

Publication number
ATE384781T1
ATE384781T1 AT00201326T AT00201326T ATE384781T1 AT E384781 T1 ATE384781 T1 AT E384781T1 AT 00201326 T AT00201326 T AT 00201326T AT 00201326 T AT00201326 T AT 00201326T AT E384781 T1 ATE384781 T1 AT E384781T1
Authority
AT
Austria
Prior art keywords
endocrine cells
undeveloped
pancreatic endocrine
cell preparation
treating diabetes
Prior art date
Application number
AT00201326T
Other languages
English (en)
Inventor
Daniel Pipeleers
Original Assignee
Beta Cell N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Cell N V filed Critical Beta Cell N V
Application granted granted Critical
Publication of ATE384781T1 publication Critical patent/ATE384781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00201326T 2000-04-12 2000-04-12 Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes ATE384781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201326A EP1146117B1 (de) 2000-04-12 2000-04-12 Verfahren zur Herstellung von entwickelten und unentwickelten Pankreasendokrinezellen, Zellpräparat und Verwendung davon zur Behandlung von Diabetes
CA2363971A CA2363971C (en) 2000-04-12 2001-11-26 A method for producing preparations of mature and immature pancreatic endocrine cells, the cell preparation and its use for treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
ATE384781T1 true ATE384781T1 (de) 2008-02-15

Family

ID=32070512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00201326T ATE384781T1 (de) 2000-04-12 2000-04-12 Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes

Country Status (8)

Country Link
US (1) US6686197B2 (de)
EP (1) EP1146117B1 (de)
AT (1) ATE384781T1 (de)
CA (1) CA2363971C (de)
DE (1) DE60037876T2 (de)
DK (1) DK1146117T3 (de)
ES (1) ES2299417T3 (de)
PT (1) PT1146117E (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359390A1 (en) * 2001-11-09 2003-05-19 Artecel Sciences, Inc. Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
WO2003068357A2 (en) * 2002-02-12 2003-08-21 Cornell Research Foundation, Inc. Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
SI1636348T1 (sl) 2003-06-20 2010-01-29 Vrije Universiteit Brussel Vub Postopek za pridobivanje beta celic iz eksokrinskih celic trebuĺ ne slinavke
MX2013011040A (es) 2011-03-29 2014-08-22 Beta Cell Nv Metodo para productos terapeuticos encapsulados y usos de los mismos.
US20150099653A1 (en) * 2011-10-28 2015-04-09 Centre National De La Recherche Scientifique Process of diagnostic, prognostic and therapeutic monitoring of solid tumors
CA2923504A1 (en) * 2013-09-19 2015-03-26 Beta-Cell Nv Method for the treatment of diabetes mellitus
CN105792775B (zh) 2013-09-24 2019-02-19 吉纳生命科学公司 用于细胞植入物的气体处理的系统
BR112019009712A2 (pt) 2016-11-15 2019-08-13 Giner Life Sciences Inc dispositivo de difusão gasosa percutânea adequado para uso com um implante subcutâneo
EP3618916A4 (de) 2017-05-04 2021-04-14 Giner Life Sciences, Inc. Robuste implantierbare gasabgabevorrichtung und verfahren, systeme und vorrichtungen damit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5050612A (en) * 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5858973A (en) * 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
US6110743A (en) * 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines

Also Published As

Publication number Publication date
CA2363971A1 (en) 2003-05-26
US20020177228A1 (en) 2002-11-28
EP1146117B1 (de) 2008-01-23
US6686197B2 (en) 2004-02-03
DE60037876D1 (de) 2008-03-13
ES2299417T3 (es) 2008-06-01
DK1146117T3 (da) 2008-05-26
CA2363971C (en) 2011-10-11
DE60037876T2 (de) 2009-01-29
EP1146117A1 (de) 2001-10-17
PT1146117E (pt) 2008-05-06

Similar Documents

Publication Publication Date Title
DE69525151T2 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
AU3513395A (en) Biological material pre-fixation treatment
DE69823361D1 (de) Herstellung von kollagen
DE69715824T2 (de) Verfahren zur herstellung eines implantierbaren verbundwerkstoffs, so hergestellte werkstoffe, und kit zur durchführung des verfahrens
DE69518437D1 (de) Verfahren zur herstellung transformierter zellen
ATE330002T1 (de) Verfahren zur herstellung von membranvesikeln
WO2002040630A3 (en) Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
ATE257396T1 (de) Verfahren zur herstellung von stabilem alginatmaterial
ATE384781T1 (de) Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes
ATE3866T1 (de) Verfahren zur herstellung einer kollagenloesung, eine solche loesung sowie ihre verwendung.
DE58907855D1 (de) Verfahren zur herstellung von rinder-pericard-materialien und ihre verwendung.
ATE373014T1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
DE69513186T2 (de) Photokatalysator, methode zur dessen herstellung, und erzeugung von wasserstoff unter verwendung des photokatalysators
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69722900D1 (de) Verfahren zur Herstellung von einer stabilen Troponin-Zubereitung und ihre Verwendung als Kalibrator/Kontrolle in Immunoassays
DE69431092T2 (de) Medizinischer Zement, Verfahren zu seiner Herstellung sowie dessen Verwendung
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
DE19981493D2 (de) Verfahren zur Herstellung einer biologischen Substanz sowie derartige Substanz und deren Verwendung
ATE246941T1 (de) Alginatfasern, verfahren zur herstellung und verwendung
ATE398664T1 (de) Verfahren zur herstellung eines multifunktionalen additivs und dessen verwendung
ATE452643T1 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
Akimoto et al. Reconstruction of basement membrane in recombinants of epidermis and dermis of chick embryonic skin in vitro: An electron microscopic study
DE69000763D1 (de) Verfahren zur herstellung von kaese und so hergestellter kaese.
ATE283284T1 (de) Verfahren zur herstellung von wespengift- allergenen mit verminderter ige-reaktivität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146117

Country of ref document: EP